Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials
Open Access
- 29 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7), e70111
- https://doi.org/10.1371/journal.pone.0070111
Abstract
Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomized controlled trials (RCTs) to compare antihypertensive effects and adverse events between mono (amlodipine or aliskiren alone) and combination therapy of both medicines. Databases for the search included Pubmed, Embase and the Cochrane Central Register of Controlled Trials. Revman v5.0 statistical program was used to analyze the data. Weighted mean differences (WMD) with a 95% confidence interval (CI) were used for the calculation of continuous data, and relative risk (RR) with a 95% CI was used for dichotomous data. We analyzed the data from 7 RCTs for a total of 6074 participants in this meta-analysis. We found that the aliskiren/amlodipine combination therapy had a stronger effect in lowering blood pressure as compared with the monotherapy using aliskiren (SBP: WMD = −10.42, 95% CI −13.03∼−7.82, P2) hypertensive and non-obese (body mass index 2) hypertensive patients. Moreover, there was no difference with the blood pressure lowering or adverse effects with regards to the combination therapy in both subgroups. We found that aliskiren/amlodipine combination therapy provided a more effective blood pressure reduction than monotherapy with either drug without increase in the occurrence of adverse events.Keywords
This publication has 31 references indexed in Scilit:
- Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesityJournal of the American Society of Hypertension, 2012
- Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndromeJournal of the American Society of Hypertension, 2011
- Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System BlockadeThe American Journal of Cardiology, 2010
- Impact of Left Ventricular Ejection Fraction on Clinical Outcomes Over Five Years After Infarct-Related Coronary Artery Recanalization (from the Occluded Artery Trial [OAT])The American Journal of Cardiology, 2010
- Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic reviewJournal of Human Hypertension, 2009
- Renin Inhibitor Aliskiren Improves Impaired Nitric Oxide Bioavailability and Protects Against Atherosclerotic ChangesHypertension, 2008
- Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patientsNephrology Dialysis Transplantation, 2008
- Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular OutcomeHypertension, 2005
- Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide‐ and kinin‐dependent mechanismBritish Journal of Pharmacology, 2002
- Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)Hypertension, 2002